Selling, General, and Administrative Costs: ADMA Biologics, Inc. vs Merus N.V.

A Comparative Analysis of SG&A Expenses: ADMA Biologics, Inc. vs Merus N.V.

In the competitive landscape of biotechnology, managing operational costs is crucial for sustainability and growth. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: ADMA Biologics, Inc. and Merus N.V., from 2014 to 2023. Over this period, ADMA Biologics, Inc. saw a staggering increase in SG&A expenses, rising by over 1,100%, from approximately $4.8 million in 2014 to nearly $59 million in 2023. Meanwhile, Merus N.V. experienced a similar upward trajectory, with expenses growing from around $3.9 million to almost $60 million, marking a 1,400% increase. This trend highlights the escalating costs associated with scaling operations and expanding market reach. As both companies continue to innovate, understanding these financial dynamics offers valuable insights into their strategic priorities and market positioning.